Retatrutide

What it is used for

Community and research context — not a medical indication or treatment advice.

• Body-weight and fat-mass reduction (clinical research)
• Appetite control / satiety
• Metabolic markers and glycaemia
• Body composition (fat vs lean mass in studies)

Retatrutide most often appears in the context of obesity and substantial body-weight reduction. Phase 2 trials assessed body-composition research, body composition and metabolic markers. In fitness / research communities it is discussed as a “next step” after semaglutide and tirzepatide — because it targets three receptors (GIP, GLP-1, glucagon). MarcinLabs covers this educationally: not therapeutic advice and not encouragement for self-treatment.

Retatrutide content is for people who want to understand mechanisms and literature (e.g. following Marcin’s journey) — not for designing self-treatment. Medical decisions always belong with a clinician.

How it works

Retatrutide is studied as a triple agonist of GIP, GLP-1 and glucagon receptors. GLP-1 and GIP are incretin pathways linked to satiety, gastric emptying and glucose handling. The glucagon component is discussed in relation to energy expenditure and fat metabolism. In the literature this is framed as both lower appetite and potentially higher energy use — the exact profile depends on dose, exposure time and study protocol.

In research, retatrutide combines incretin pathways (GLP-1/GIP) with a glucagon component that may influence energy expenditure and fat metabolism. The exact effect profile depends on dose, exposure time and study protocol.